shiningsurekha Profile Banner
SurekhaYadav MD Profile
SurekhaYadav MD

@shiningsurekha

Followers
207
Following
601
Media
14
Statuses
243

Nuclear Medicine Physician, Molecular Imaging and Theranostics.|Tweets are my own

San Francisco, CA
Joined December 2010
Don't wanna be here? Send us removal request.
@shiningsurekha
SurekhaYadav MD
3 months
These findings suggest there may be a clear advantage to using ¹⁷⁷Lu-PSMA-617 before chemotherapy, when PSMA expression is likely higher and more uniform. 💡 This could help maximize treatment efficacy by better targeting PSMA-positive lesions before they downregulate.
0
0
1
@shiningsurekha
SurekhaYadav MD
3 months
Key takeaways : Taxane-based chemotherapy is associated with reduced PSMA uptake, particularly in:. 📌 Patients with high baseline PSMA expression (SUVmean ≥ 10), who showed an average -18% decrease. 📌 Those who responded well to chemo (greater PSMA decline in PSA responders).
0
0
1
@shiningsurekha
SurekhaYadav MD
3 months
Our latest study, coinciding perfectly with FDA's expanded approval of Pluvicto. Taxane-based chemo is associated with ⬇️ PSMA uptake 👉🏼EJNMMI Research: Big Thanks to @thomashopemd for his excellent mentorship & our wonderful co-authors! . More below:
Tweet media one
2
0
4
@shiningsurekha
SurekhaYadav MD
4 months
RT @PSMAconference: What is the best combination therapy with Lu-PSMA? Let’s hear some insights from the Australian prospective trials in t….
0
5
0
@shiningsurekha
SurekhaYadav MD
4 months
RT @dr_coops: Great summary re: avoiding false positive PSMA pitfalls from Irene Burger #APCCCDiagnostics25
Tweet media one
0
43
0
@shiningsurekha
SurekhaYadav MD
5 months
RT @gu_onc: Breaking news podcast - ENZA-P reports OS benefit for combo of enza + LuPSMA. @drlouiseemmett reports data at @ASCO GU and publ….
0
6
0
@shiningsurekha
SurekhaYadav MD
5 months
RT @UCSFimaging: The @PSMAconference will gather leading experts to discuss the latest in PSMA PET imaging & radioligand therapies. Hear fr….
0
6
0
@shiningsurekha
SurekhaYadav MD
6 months
RT @DrMHofman: SPECT deserves RESPECT! . @drlouiseemmett makes the argument that it is a powerful tool for theranostics ➤ enabling early,….
0
26
0
@shiningsurekha
SurekhaYadav MD
7 months
RT @thomashopemd: We are excited to host the second PSMA PET conference with @UCLATheranostic and the @PCF_Science in March. The abstract d….
0
10
0
@shiningsurekha
SurekhaYadav MD
11 months
Imagine the future of precision medicine with evidence that is impossible to ignore! Our latest study shows why post-treatment SPECT scans are a must. Next time you’re ordering, let these numbers do the talking!
Tweet media one
@thomashopemd
Thomas Hope
11 months
1) We recently reported our experience with post-treatment SPECT in PSMA RLT and its impact on management. Nearly 50% of patients had a change in treatment! Post-treatment imaging has a huge impact, and allows us to follow disease at each treatment (.
1
0
6
@shiningsurekha
SurekhaYadav MD
1 year
Here’s a quick link to the full article for those interested:.
0
0
0
@shiningsurekha
SurekhaYadav MD
1 year
'Patients imaged with 18F-DCFPyL demonstrated clinical benefit to PSMA RLT comparable to those imaged with 68Ga-PSMA-11, and either agent can be used for screening patients' - excerpts from our latest work @thomashopemd @koshkin85 @UCSFimaging @FrontiersIn
Tweet media one
1
0
2
@shiningsurekha
SurekhaYadav MD
1 year
RT @UCSFimaging: New in #Theranostics from @UCSFimaging's Drs. Anil Bidkar (@anilbidkar1), Luann Zerefa, Surekha Yadav (@shiningsurekha), H….
0
4
0
@shiningsurekha
SurekhaYadav MD
1 year
Shoutout to the incredible team behind this review @anilbidkar1 @flavell_rob and Co-authors ! Grateful for the opportunity @flavell_rob and to be a part of this project!!.
@flavell_rob
Rob Flavell
1 year
Congrats to @anilbidkar1 @shiningsurekha and co-authors on the timely review on Actinium-225 targeted alpha particle therapy for prostate cancer! Lots of promise for this treatment modality. #Theranostics
Tweet media one
0
1
7
@shiningsurekha
SurekhaYadav MD
1 year
RT @CalaisJeremie: We can do better than a fixed set of 6 cycles of LuPSMA at a 6-week time interval ! .Great multicenter data of >100 pati….
0
14
0
@shiningsurekha
SurekhaYadav MD
1 year
RT @drlouiseemmett: @thomashopemd @shiningsurekha @UCSFimaging @JournalofNucMed @SNM_MI @NANETS1 A great goal! SPECT/CT after PRRT provides….
0
2
0
@shiningsurekha
SurekhaYadav MD
1 year
Pairing of a promising project with an exceptional mentor @thomashopemd ! Excited and hopeful about the utility of SPECT/CT in #radioligandtherapies @UCSFimaging @JournalofNucMed @NANETS1.
@thomashopemd
Thomas Hope
1 year
In March, @shiningsurekha published our experience on the impact of post-treatment SPECT on patient management. We are trying to move people from thinking about SPECT as only for dosimetry, and focus on its role in response assessment and using it to follow patients over time.
Tweet media one
0
1
11
@shiningsurekha
SurekhaYadav MD
1 year
RT @drlouiseemmett: ENZA-p trial @TheLancetOncol .Enzalutamide + adaptive-dosed (2 or 4) 177 Lu-PSMA617 vs enza al….
0
44
0
@shiningsurekha
SurekhaYadav MD
1 year
RT @CalaisJeremie: SPECT images obtained +24h after administration of Lu177 therapy can provide valuable information and can impact patient….
0
11
0
@shiningsurekha
SurekhaYadav MD
1 year
Is EXCITED about: .- Upcoming talks at #SNMMI #MidWinterMeeting by some of the distinguished figures in theranostics @thomashopemd @lisabodei @flavell_rob .- My talk on Volumetric Analysis in SSTR Imaging .- Presenting our results on Impact of Post treatment Imaging in PRRT.
0
0
11